Clinical trial · no report yet · Phase 3
CONTACT-02
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- NCT04446117 ↗
- Active not recruiting
- Exelixis
- 119 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 86 | |
| Podcasts | 16 | |
| YouTube | 14 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Metastatic Prostate Cancer; Prostate Adenocarcinoma
- Interventions
- Cabozantinib; Atezolizumab; Abiraterone Acetate; Enzalutamide; Prednisone
- Arms
- Experimental Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 575
- Primary outcomes
- Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)
- Duration of Overall Survival (OS)
- Sponsor
- Exelixis with Roche-Genentech, Takeda
- Start
- Oct 19, 2020
- Primary completion
- Apr 19, 2024
- Results posted
- Yes
- Registry record
- NCT04446117 · updated Dec 18, 2025
Publications
linked from the registry- Agarwal N, Azad AA, Carles J, Matsubara N, Oudard S, Saad F, Merseburger AS, Soares A, McGregor BA, Zurawski B, Tsiatas M, North S, Bondarenko I, Alfie M, Bournakis E, Antonuzzo L, Evilevitch L, Simmons A, Wang F, Ferraldeschi R, Nandoskar P, Pal SK. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 2025 Jul;26(7):860-876. doi: 10.1016/S1470-2045(25)00209-8. Epub 2025 Jun 13. PubMed 40523369
- Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17. PubMed 35034502